BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
BioCentury | Jun 28, 2019
Clinical News

June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more

AZ's Imfinzi shows survival benefit in Phase III for SCLC AstraZeneca plc (LSE:AZN; NYSE:AZN) said an interim analysis of the Phase III CASPIAN trial showed Imfinzi plus etoposide and platinum-based chemotherapy met the primary endpoint...
BioCentury | Jun 26, 2019
Clinical News

June 25 Clinical Quick Takes: Minerva meets in insomnia; plus Aldeyra, Genkyotex and more

Minerva rises with insomnia data Seltorexant (MIN-202) from Minerva Neurosciences Inc. (NASDAQ:NERV) met the primary endpoint of reducing Latency to Persistent Sleep (LPS) at night 1 vs. placebo (p≤0.001) in a Phase IIb trial to...
BioCentury | Apr 22, 2019
Distillery Therapeutics

GPX4 inhibitors for ovarian and renal clear cell carcinomas

DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer; renal cancer Cell culture and mouse studies identified GPX4 inhibitors that could help treat ovarian clear cell carcinoma and clear cell renal cell carcinoma (ccRCC). Analysis of a database...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BioCentury | Nov 30, 2017
Clinical News

Sound reports Phase Ib data for SPI-1005 in Meniere's disease

In October, Sound Pharmaceuticals Inc. (Seattle, Wash.) reported top-line data from a Phase Ib trial in 40 patients with Meniere’s disease showing that oral ebselen (SPI-1005) for 21 days improved low frequency hearing in 55%...
BioCentury | Nov 17, 2017
Company News

Monopar acquires cancer candidate from Gem, raises $9.7M

Cancer company Monopar Therapeutics Inc. (Northbrook, Ill.) said it acquired candidates including GPX-150 from Gem Pharmaceuticals LLC (Pelham, Ala.) and closed $9.7 million in financing. Gem invested $5 million. Monopar raised the remainder in two...
BioCentury | Nov 6, 2017
Distillery Therapeutics


INDICATION: Cancer; solid tumors Cell culture and mouse studies suggest inhibiting GPX4 could help treat relapsing, drug-resistant cancers. In human breast, lung, melanoma and ovarian cancer cell lines, a GPX4 inhibitor tool compound induced higher...
BioCentury | Nov 2, 2017
Preclinical News

Researchers suggest GPX4 inhibition to treat drug-resistant cancer

In a paper published in Nature , researchers at the University of California San Francisco and colleagues showed that persister cells from a range of cancers depend on glutathione peroxidase 4 (GPX4) for survival, suggesting that...
Items per page:
1 - 10 of 69